EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety
Eligible age
12+ yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a randomized, double-Blind, placebo-controlled study to evaluate the efficacy and safety of exaluren in Alport Syndrome patients with nonsense mutations in COL4A3/4/5 genes. Targeted 24 patients aged 12 and older will be enrolled in the trial. The study will be comprised of the following periods for each participant: * a Screening period of up to 6 weeks (42 days) * a total Treatment Period of exaluren 0.75 mg/kg or placebo administered daily subcutaneously for 32 weeks: Part 1: patients are randomized to either exaluren or placebo for 16 weeks. Part 2: all patients across both randomized arms receive exaluren for 16 additional weeks. * a safety/efficacy Follow-up Period of 4 weeks after the last treatment
Sponsor: Eloxx Pharmaceuticals, Inc.
You may qualify if…
- ✓ A confirmed diagnosis of X-linked or autosomal recessive Alport Syndrome with a documented nonsense mutation of COL4A5 in a male or nonsense mutation of COL4A3 or COL4A4 (male or female)
- ✓ eGFR\>40 ml/min/1.73 m2
- ✓ Urinary protein based on two spot urine collections \[urine protein/creatinine ratio (UPCR) ≥ 300 mg/g\]
- ✓ Stable regimen of ACEi/ARB for at least 12 weeks before Day 1
You may not qualify if…
- ✕ History of any organ transplantation
- ✕ Liver disease characterized by cirrhosis or portal hypertension. Participants with alanine aminotransferase (ALT), aspartate aminotransferase (AST), and/or a total bilirubin 1.5 times the upper limit of normal (ULN) will be excluded
- ✕ History of dialysis
- ✕ Acute kidney injury within 4 weeks before screening
- ✕ Active dizziness
Where it's recruiting
Los Angeles · Stanford
Denver
Minneapolis
Hackensack
Philadelphia
San Antonio
Source: ClinicalTrials.gov · NCT07523581 · last updated 2026-09-30